Hi Angel Eyes,
Thanks for your questions.
This treatment is being assessed for use after 2 or more anti-HER2 treatments. For example, previous treatments might include trastuzumab (Herceptin) with pertuzumab (Perjeta) and trastuzumab emtansine (Kadcyla) too.
The group of patients that could be eligible for this treatment will be considered as part of the assessment of this treatment for use on the NHS.
Thanks and best wishes,
Sorry if I appear stupid but would I be eligible for this drug? I am HER2 positive and currently have Trastuzumab and Pertuzumab as part of my current secondary treatment.
Could I only go onto this drug if both Herceptin and Perjeta fail? Is that correct? Is it considered a first or second line treatment?
My name’s Holly and I work in the Policy, Evidence and Influencing Team at Breast Cancer Now.
The drug trastuzumab deruxtecan (also known as Enhertu) is being assessed for use on the NHS by the National Institute for Health and Care Excellence (NICE) for the treatment of HER2 positive secondary breast cancer, after 2 or more anti-HER2 treatments.
We're currently gathering evidence and insights to help inform our response on what access to this drug would mean for this group of patients. As part of this we would like to speak to anybody who has received the drug treatment trastuzumab deruxtecan to hear your experiences and inform our work.
If you are able to help, please complete this short form https://breastcancernow.org/about-us/tell-us-your-story by 12th August.
Any questions, please let me know.